

. . . , . . . , . . .
2, «
. . . », .

CONDITION AND PERSPECTIVES OF ARTERIAL HYPERTENSION IN WOMEN
M.Y. Plastun, V.N. Zorin, V.A. Tsvetkov

SUMMARY

The prevalence of arterial hypertension among women tends to increase. Prevention methods have no sufficient positive effect so it is necessary to develop preventive programs for a certain contingent of women depending on the pathogenesis of hypertension. The efficacy of prevention is increased only by antihypertensive therapy with usage of β -blockers, diuretics, calcium channel blockers and antagonists of imidazoline receptors.

. . . , . . . , . . .

Year	Prevalence (%)	Number of cases
2004	50,0%	1-
2004	26,0	2-
2004	31,3%	3-
2004	10-	
2004	52,1	10-
2004	60,5%	
2004	42,8	
2004	63,4%	
2004	29,9	
2004	37,5%	
2004	9,7	
2004	14,2%	
2004	57,5	
2004	48,4%	
2004	29,4	
2004	29,6%	
2004	29,7	
2004	29,3%	
2004	42,5	
2004	51,6	
2004	55,0	
2004	1,8	

31,5% [1,3]. 60,4% 67,5% -

2010 , 1 11 889 737 26,8 53,8% , -

31,5% 9,6 24,9%. -

1999 (, , -

). , , -

55,0 50,0% - :

1- 26,0

31,3% 2- 35-44 (19,0% 25-34

3- (55,6%). (25-34)

70,0%

24,1 34,4% 2- -

53,7 45,9% - ,

1- (>0,05). ; 55

1,0% 18-24 65,9% 55-64 - 74,4% , 80,0%, 52,3%

4,6% 25-34 76,2% 55-64 . 11,5 17,7% -

35 45 1,6 4,3 . -

5,3 . . (>0,05), - 3,1 . . (>0,05). -

(57,5%) -

(35,8 35,5% - 3,8 . . (>0,05). -

). 8,4 . . (>0,05), - 5,8

46,2% 38,4% . . (>0,05). -

85% () -

(), -

[2]. -

10.08.98 247 « -

35,8% 30.12.92 -

12,1% 206 « -

» . , -

-37,9 11,6% -

89,7% 77,3% -

87,9 83,3% - 10,7% -

-36,0%

4,6 -

2,1 - 25,5% -

[3]. -

-13,6% , -

-2,9% , 8,7% -

-

1- ;

2- () [5].

II (,)

GEMENI

[11].

48,4%

51,5% -

(51,3%) - (29,3%).

5,2%, 5,6% II - 0,9%. [10].

7,3% -0,4%.

ep o II

Mild SR

Hypertension Study, [6].

II

().

a

().

ASCOT [2,4].

1. « » // .-2010.- 6.- .48-52.

2. // .-2003.- 3.- .6-10.

3. 20

., 2008.- .40.

4. ([7].)// .-2009.- 6.- .15.- .707-709.

5. Fizman E.Z., Tenenbaum A., Pines A. Systemic hypertension in postmenopausal women: a clinic approach. *Curr Hypertens Rep* 2002; 4; 464-70.

6. Gueyffier F., Boutitie F., Boissel J.P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. *The INDANA Investigators. Ann Intern Med.* 1997; 126; 761-7.

7. Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. *J. Hypertens* 1999; 17(3): 29-35.

8. Mosca L., Appel L.J., Benjamin E.J., et al, for the American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women.

CA US (, 2006) (, 2006)

Circulation. 2004;109(5):672-693/

9. Mosca L., Banka D.L., Benjamin E.J., et al, for the American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11): 1481-1501.

10. Pechere-Bertschitz A., Burnier M. Female sex

hormones, salt and blood pressure regulation. Am J Hypertens 2004;17: 994-1001.

11. 2007 European Society of Hypertension – European Society of Cardiology guidelines for management of arterial hypertension// J.Hypertension.- 2007.- Vol. 25.- P. 1105-1187.